12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AHRO-001: Phase I started

AtheroNova said its partner OOO CardioNova, a subsidiary of Maxwell Biotech, began a double-blind, placebo-controlled, Russian Phase I trial to evaluate ascending...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >